A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954

Trial Profile

A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs TD 8954 (Primary)
  • Indications Gastrointestinal motility disorders
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 23 Mar 2018 to 31 Jul 2018.
    • 18 Oct 2017 Planned primary completion date changed from 23 Mar 2018 to 31 Jul 2018.
    • 18 Oct 2017 Planned initiation date changed from 26 Sep 2017 to 22 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top